SAFETY, TOLERABILITY, AND BIOLOGICAL ACTIVITY OF AXA1125 AND AXA1957 IN A PROSPECTIVE 16-WEEK RANDOMIZED, PLACEBO-CONTROLLED STUDY IN SUBJECTS WITH NAFLD WITH AND WITHOUT TYPE 2 DIABETES

被引：0
|
作者：
Harrison, Stephen A. [1 ]
Gunn, Nadege T. [2 ]
Baum, Seth J. [3 ]
Younes, Ziad H. [4 ]
Kohli, Anita [5 ]
Patil, Rashmee [6 ]
Koziel, Margaret J. [7 ]
Chera, Harinder [7 ]
Zhao, Jeff [7 ]
Chakravarthy, Manu V. [7 ]
机构：
[1] Pinnacle Clin Res Ctr, San Antonio, TX USA
[2] Pinnacle Clin Res, San Antonio, TX USA
[3] Excel Med Clin Trials, Boca Raton, FL USA
[4] Gastro One, Germantown, TN USA
[5] Arizona Liver Hlth, Chandler, AZ USA
[6] South Texas Res Inst, Edinburg, TX USA
[7] Axcella Hlth Inc, Cambridge, MA USA
来源：
HEPATOLOGY | 2020年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1694
引用
收藏
页码：1032 / 1033
页数：2
相关论文
共 44 条
  • [31] A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Four-Period, Crossover Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Three Dose Levels of PB201 as Monotherapy in Subjects with Type 2 Diabetes Mellitus
    Xu, Min
    DIABETES, 2021, 70
  • [32] A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosightazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy
    Davidson, Jaime A.
    McMorn, Stephen O.
    Waterhouse, Brian R.
    Cobitz, Alexander R.
    CLINICAL THERAPEUTICS, 2007, 29 (09) : 1900 - 1914
  • [33] A Multicenter, Randomized, Double-Blind, Placebo-Controlled, and Dose-Increasing Study on the Safety, Tolerability and PK/PD of Multiple Doses of HSK7653 by Oral Administration in Patients with Type 2 Diabetes Mellitus in China
    Bai, Nan
    Wang, Jin
    Liang, Wenxin
    Gao, Leili
    Cui, Wei
    Wu, Qinghe
    Li, Fangqiong
    Ji, Linong
    Cai, Yun
    DIABETES THERAPY, 2024, 15 (01) : 183 - 199
  • [34] A Multicenter, Randomized, Double-Blind, Placebo-Controlled, and Dose-Increasing Study on the Safety, Tolerability and PK/PD of Multiple Doses of HSK7653 by Oral Administration in Patients with Type 2 Diabetes Mellitus in China
    Nan Bai
    Jin Wang
    Wenxin Liang
    Leili Gao
    Wei Cui
    Qinghe Wu
    Fangqiong Li
    Linong Ji
    Yun Cai
    Diabetes Therapy, 2024, 15 : 183 - 199
  • [35] Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study)
    Ahn, Chang Ho
    Han, Kyung Ah
    Yu, Jae Myung
    Nam, Joo Young
    Ahn, Kyu Jeung
    Oh, Tae Keun
    Lee, Hyoung Woo
    Lee, Dae Ho
    Kim, Jaetaek
    Chung, Choon Hee
    Park, Tae Sun
    Kim, Byung Joon
    Park, Seok Won
    Park, Hyeong Kyu
    Lee, Kwang Jae
    Kim, Sang-Wook
    Park, Jeong Hyun
    Ko, Kwan Pyo
    Kim, Chong Hwa
    Lee, Hyunjin
    Jang, Hak Chul
    Park, Kyong Soo
    DIABETES OBESITY & METABOLISM, 2017, 19 (05): : 635 - 643
  • [36] A 12-Week, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Three Dose-Escalation Algorithms of Tirzepatide, a Novel Dual GIP and GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes
    Frias, Juan P.
    Nauck, Michael A.
    Van, Joanna
    Benson, Charles
    Bray, Ross
    Milicevic, Zvonko
    Haupt, Axel
    Robins, Deborah A.
    DIABETES, 2019, 68
  • [37] GPR40 Agonist MK-8666: A Phase 1b, Randomized, Placebo-Controlled, Multiple-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics in Type 2 Diabetes Mellitus Patients
    Krug, Alexander W.
    Railkar, Radha
    Musser, Bret
    Cote, Josee
    Ederveen, Twan
    Kauh, Anya
    Vaddady, Pavan
    Tatosian, Daniel
    Kothare, Prajakti
    DIABETES, 2016, 65 : A281 - A281
  • [38] \Safety/tolerability, efficacy and pharmacokinetics of 600-μg cotadutide in Japanese type 2 diabetes patients with a body mass index of 25 kg/m2 or higher: A phase I, randomized, double-blind, placebo-controlled study
    Asano, Michiko
    Sekikawa, Akiko
    Sugeno, Masatoshi
    Matsuoka, Osamu
    Robertson, Darren
    Hansen, Lars
    DIABETES OBESITY & METABOLISM, 2023, 25 (08): : 2290 - 2299
  • [39] Resveratrol supplementation decreases blood glucose without changing the circulating CD14+ CD16+ monocytes and inflammatory cytokines in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
    Khodabandehloo, Hadi
    Seyyedebrahimi, ShadiSadat
    Esfahani, Ensieh Nasli
    Razi, Farideh
    Meshkani, Reza
    NUTRITION RESEARCH, 2018, 54 : 40 - 51
  • [40] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
    Rosenstock, Julio
    Brazg, Ronald
    Andryuk, Paula J.
    Lu, Kaifeng
    Stein, Peter
    CLINICAL THERAPEUTICS, 2006, 28 (10) : 1556 - 1568
12345